Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“Pleased to shared with the Universe Hot off the press
Simultaneously published with the NEW ESMO Tumour Agnostic Tack “Rethinking Cancer Drug Development through Tumor-Agnostic Precision Medicine” at Cancer Discovery journal.
Read this paper that will be presented at the special session at ESMO.”
Title: Rethinking Cancer Drug Development through Tumor-Agnostic Precision Medicine
Author: Vivek Subbiah
Read the Full Article on Cancer Discovery
More posts featuring Vivek Subbiah.